PMID- 28758430
OWN - NLM
STAT- MEDLINE
DCOM- 20180727
LR  - 20180727
IS  - 1205-7541 (Electronic)
IS  - 0008-4212 (Linking)
VI  - 96
IP  - 1
DP  - 2018 Jan
TI  - Calpain inhibitor I attenuates atherosclerosis and inflammation in 
      atherosclerotic rats through eNOS/NO/NF-kappaB pathway.
PG  - 60-67
LID - 10.1139/cjpp-2016-0652 [doi]
AB  - We previously reported that calpain, the Ca(2+)-sensitive cysteine protease, gets 
      involved in atherogenesis. This study aimed to investigate the effects of calpain 
      inhibitor I (CAI, 5 mg/kg per day) with or without N(G)-nitro-l-arginine-methyl 
      ester (l-NAME) (100 mg/kg per day), the inhibitor of nitric oxide synthase (NOS), 
      on atherosclerosis and inflammation in a rat model induced by high-cholesterol 
      diet (HCD). The results demonstrated HCD increased protein expression of 
      calpain-1 but not calpain-2 in aortic tissue. In addition, CAI reduced the 
      thickness of atherosclerotic intima compared with HCD group, which was weakened 
      by the l-NAME combination. CAI with or without l-NAME decreased the activity of 
      calpain in the aorta. Also, CAI decreased the expressions of vascular cell 
      adhesion molecule-1 (VCAM-1), intracellular cell adhesion molecule-1 (ICAM-1), 
      and monocyte chemoattractant protein-1 (MCP-1) in the aorta at the levels of both 
      mRNA and protein. Furthermore, CAI increased the activity and the protein 
      expression of endothelial NOS (eNOS) accompanied by increased content of NO and 
      downregulated the protein expression of nuclear factor kappaB (NF-kappaB) of the nucleus 
      in the aorta. However, the abovementioned effects were at least partly cancelled 
      by l-NAME except for the protein expression of eNOS. The results suggested that 
      CAI attenuated atherosclerosis and inflammation through eNOS/NO/NF-kappaB pathway.
FAU - Yu, Lan
AU  - Yu L
AD  - a Key Laboratory of Cardiovascular and Cerebrovascular Drug Research of Liaoning 
      Province, Jinzhou Medical University, Jinzhou 121001, China.
AD  - b Central Hospital of Yingkou Development Areas, Yingkou 115007, China.
FAU - Yin, Meihui
AU  - Yin M
AD  - a Key Laboratory of Cardiovascular and Cerebrovascular Drug Research of Liaoning 
      Province, Jinzhou Medical University, Jinzhou 121001, China.
FAU - Yang, Xueyan
AU  - Yang X
AD  - a Key Laboratory of Cardiovascular and Cerebrovascular Drug Research of Liaoning 
      Province, Jinzhou Medical University, Jinzhou 121001, China.
AD  - c Internal Medicine-Cardiovascular Departments, the First Affiliated Hospital of 
      Jinzhou Medical University, Jinzhou 121001, China.
FAU - Lu, Meili
AU  - Lu M
AD  - a Key Laboratory of Cardiovascular and Cerebrovascular Drug Research of Liaoning 
      Province, Jinzhou Medical University, Jinzhou 121001, China.
FAU - Tang, Futian
AU  - Tang F
AD  - a Key Laboratory of Cardiovascular and Cerebrovascular Drug Research of Liaoning 
      Province, Jinzhou Medical University, Jinzhou 121001, China.
FAU - Wang, Hongxin
AU  - Wang H
AD  - a Key Laboratory of Cardiovascular and Cerebrovascular Drug Research of Liaoning 
      Province, Jinzhou Medical University, Jinzhou 121001, China.
LA  - eng
PT  - Journal Article
DEP - 20170730
PL  - Canada
TA  - Can J Physiol Pharmacol
JT  - Canadian journal of physiology and pharmacology
JID - 0372712
RN  - 0 (Antigens, CD)
RN  - 0 (Antigens, Differentiation, Myelomonocytic)
RN  - 0 (CD68 antigen, human)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Glycoproteins)
RN  - 0 (Lipids)
RN  - 0 (NF-kappa B)
RN  - 0 (Vascular Cell Adhesion Molecule-1)
RN  - 0 (calpain inhibitors)
RN  - 126547-89-5 (Intercellular Adhesion Molecule-1)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - EC 1.14.13.39 (Nitric Oxide Synthase Type III)
RN  - EC 3.4.22.- (Calpain)
SB  - IM
MH  - Animals
MH  - Antigens, CD/metabolism
MH  - Antigens, Differentiation, Myelomonocytic/metabolism
MH  - Aorta/drug effects/enzymology
MH  - Atherosclerosis/blood/complications/*drug therapy/*metabolism
MH  - Calpain/metabolism
MH  - Cell Nucleus/drug effects/metabolism
MH  - Chemokine CCL2/metabolism
MH  - Glycoproteins/pharmacology/*therapeutic use
MH  - Inflammation/blood/complications/*drug therapy/*metabolism
MH  - Intercellular Adhesion Molecule-1/metabolism
MH  - Lipids/blood
MH  - Male
MH  - NF-kappa B/*metabolism
MH  - Nitric Oxide/*metabolism
MH  - Nitric Oxide Synthase Type III/*metabolism
MH  - Protein Transport/drug effects
MH  - Rats, Sprague-Dawley
MH  - Signal Transduction/drug effects
MH  - Vascular Cell Adhesion Molecule-1/metabolism
OTO - NOTNLM
OT  - NF-kappaB
OT  - atherosclerosis
OT  - atherosclerose
OT  - calpain inhibitor CAI
OT  - endothelial nitric oxide synthase
OT  - inhibiteur de la calpaine ICA
OT  - nitric oxide
OT  - oxyde nitrique
OT  - oxyde nitrique synthase endotheliale
EDAT- 2017/08/02 06:00
MHDA- 2018/07/28 06:00
CRDT- 2017/08/01 06:00
PHST- 2017/08/02 06:00 [pubmed]
PHST- 2018/07/28 06:00 [medline]
PHST- 2017/08/01 06:00 [entrez]
AID - 10.1139/cjpp-2016-0652 [doi]
PST - ppublish
SO  - Can J Physiol Pharmacol. 2018 Jan;96(1):60-67. doi: 10.1139/cjpp-2016-0652. Epub 
      2017 Jul 30.